MAZE
HEALTHCAREMaze Therapeutics, Inc. Common Stock
AI Insight
What's Moving MAZE Today?
No stock-specific AI insight has been generated for MAZE yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$9.83$53.65
$26.41
Fundamentals
Market Cap$1.4B
P/E Ratio—
EPS$-2.35
Dividend Yield—
Dividend / Share—
ROE-38.7%
Profit Margin—
Debt / Equity—
Trading
Volume649K
Avg Volume (10D)—
Shares Outstanding55.3M
MAZE News
21 articles- Maze Therapeutics Phase 2 Kidney Data Sparks Questions On Upside And RiskYahoo Finance·Jun 13, 2026
- MAZE: Both director nominees and the auditor appointment were approved by majority voteTradingView·Jun 8, 2026
- Maze Therapeutics (MAZE): 8 Oversold Stocks to Buy Right NowYahoo Finance·Jun 8, 2026
- Maze Therapeutics' CEO Sold Over 30,000 Company Shares. What Does That Mean for Investors?Motley Fool·Jun 5, 2026
- Maze Therapeutics to Participate in Two Upcoming Investor ConferencesGlobeNewswire·May 27, 2026
- Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in SharesMotley Fool·May 17, 2026
- Industry Analysts Just Made A Stunning Upgrade To Their Maze Therapeutics, Inc. (NASDAQ:MAZE) Revenue ForecastsYahoo Finance·May 17, 2026
- Maze Therapeutics, Inc. (MAZE) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 12, 2026
- Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent HighlightsYahoo Finance·May 12, 2026
- A Look At Maze Therapeutics (MAZE) Valuation After Recent Share Price WeaknessYahoo Finance·May 12, 2026
- Maze Therapeutics CSBO Sells 7,500 Shares for $190,000 After Strong Trial Results and Q4 FinancialsMotley Fool·May 7, 2026
- What Makes Maze Therapeutics (MAZE) One of the Best Oversold Small-Cap Stocks to BuyYahoo Finance·Apr 26, 2026
- Maze Therapeutics Announces $150 Million Registered OfferingGlobeNewswire Inc.·Apr 22, 2026
- Truist Updates Maze Therapeutics, Inc. (MAZE) Model for Share Count and Warrant ImpactYahoo Finance·Apr 21, 2026
- Here is why Maze Therapeutics (MAZE) is Among the Top 8 Oversold Strong Buy-Rated StocksYahoo Finance·Apr 8, 2026
- Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors.The Motley Fool·Apr 4, 2026
- After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Maze Therapeutics, Inc. (MAZE)Yahoo Finance·Mar 27, 2026
- Why Maze Therapeutics Plunged 35% Despite 'Overwhelming Positive' DataYahoo Finance·Mar 25, 2026
- Maze Therapeutics Shares Phase II HORIZON Data: MZE829 Cuts Proteinuria in APOL1 Kidney DiseaseMarketbeat·Mar 25, 2026
- Maze Insider Reports $736K Sale. Here's What Investors Should Know as Stock Plunges 33%Motley Fool·Mar 25, 2026
- Maze set to target Vertex as kidney disease drug succeeds in Phase II trialClinicaltrialsarena·Mar 25, 2026
All 21 articles loaded
Price Data
Open$25.31
Previous Close$26.41
Day High$26.46
Day Low$25.24
52 Week High$53.65
52 Week Low$9.83
52-Week Range
$9.83$53.65
$26.41
Fundamentals
Market Cap$1.4B
P/E Ratio—
EPS$-2.35
Dividend Yield—
Dividend / Share—
ROE-38.7%
Profit Margin—
Debt / Equity—
Trading
Volume649K
Avg Volume (10D)—
Shares Outstanding55.3M
About Maze Therapeutics, Inc. Common Stock
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. The company is headquartered in South San Francisco, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—